Longitudinal Effects of Diabetes-Associated Variation in TCF7L2 on Glucagon and Insulin Secretion in Non-Diabetic Humans

Overview

About this study

The goal of this study is to determine the role of postprandial glucagon suppression and insulin secretion in the progression of glucose intolerance in people with diabetes-associated variation in TCF7L2.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Individuals who previously underwent a 2 hour, 7-sample oral glucose tolerance test as part of IRB# 348-05 (n:190); IRB# 07-005203 (n:187) and IRB# 11-007525 (n:135) and on who we have minimal model indices of insulin secretion and insulin action. We propose to recruit subjects from these cohorts who are homozygous for the disease-associated allele (T) at rs7903146 or homozygous for the disease-protecting allele (C).

Exclusion Criteria:

  • No known active systemic illness
  • Be taking any medication that could affect glucose metabolism
  • No history of abdominal surgery (other than appendectomy or tubal ligation).
  • Subjects with a fasting blood glucose >126 mg/dL

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions